Atlas Trials

The Combination of Atorvastatin, Acetylcysteine and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Clinical trial NCT03460808 · UNKNOWN

Trial details

NCT number
NCT03460808
Sponsor
Peking University People's Hospital
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Immune Thrombocytopenia
Start date
2018-03-10
Primary completion
2020-01-01
Enrollment
200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.